Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

The Human Genome Project, launched in 1990 and completed in 2003, also moved the needle. Scientists had successfully ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

With the bull market starting its fourth year, and yields on U.S. debt falling to the lowest levels since early this year, ...

In a recent video, Keerthika Govindhasamy or Keerthi History, a YouTuber with millions of followers, attempts to establish ...

India faces a silent anaemia epidemic, with rising cases across all demographics. In most cases, public tend to disregard its ...